386 related articles for article (PubMed ID: 35443825)
21. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
22. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
24. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution.
Porcelli T; Luongo C; Sessa F; Klain M; Masone S; Troncone G; Bellevicine C; Schlumberger M; Salvatore D
Endocrine; 2021 Aug; 73(2):358-366. PubMed ID: 33537956
[TBL] [Abstract][Full Text] [Related]
25. Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios.
Zafón C; Castelo B
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):3-4. PubMed ID: 36202604
[TBL] [Abstract][Full Text] [Related]
26. Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Sakai R; Nakayama H; Toda S; Masudo K
Medicine (Baltimore); 2019 Oct; 98(42):e17588. PubMed ID: 31626129
[TBL] [Abstract][Full Text] [Related]
27. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
[No Abstract] [Full Text] [Related]
28. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
29. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
30. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
[TBL] [Abstract][Full Text] [Related]
31. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
34. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M
Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491
[TBL] [Abstract][Full Text] [Related]
35. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib.
Ling Y; Xiong X; Luo J; Zou Q; Chen P; Pan L; Long M; Feng H; Ouyang W
Front Endocrinol (Lausanne); 2023; 14():1200932. PubMed ID: 37534207
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
De Leo S; Di Stefano M; Persani L; Fugazzola L; Colombo C
Endocrine; 2021 May; 72(2):462-469. PubMed ID: 32885329
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.
Costa R; Carneiro BA; Chandra S; Pai SG; Chae YK; Kaplan JB; Garrett HB; Agulnik M; Kopp PA; Giles FJ
Drug Des Devel Ther; 2016; 10():873-84. PubMed ID: 27013865
[TBL] [Abstract][Full Text] [Related]
39. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib.
Platini F; Cavalieri S; Alfieri S; Bergamini C; Resteghini C; Bottiglieri A; Colombo E; Mazzeo L; Licitra L; Paolini B; Seregni E; Locati LD
Endocrine; 2021 Sep; 73(3):641-647. PubMed ID: 33797698
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
